The Fight Against the Slime: Can We Ever Win?



Fig. 21.1
(a, b) Progressive acetabular component mobilization; (c) X-ray after revision with an anti-protrusion cage; (d) catastrophic clinical aspect with exposure of the bone of the implant due to infection; (eh) resection arthroplasty still in treatment 1 year after the outset of the infection



Schamalzried, in order to better characterize the cause of prosthetic joint infection (PJI), described four different modes of infection: mode 1, intraoperative surgical contaminations; mode 2, hematogenous spread; mode 3, a recurrence of sepsis in a previously infected hip; and mode 4, contiguous spread of infection from local source (Schamalzried et al. 1992).

Another useful way to classify the periprosthetic joint infections (PJIs) is according to Coventry’s classification that distinguishes three categories: acute postoperative infections (infection is caused by contamination at the time of the operation), delayed infections (usually at least 8 weeks after operation in the form of an indolent, chronic, low-grade infection), and late hematogenous infections (it can happen at any time with a presentation similar to that of acute infection) (Coventry 1975).

From an etiological point of view, PJIs are mainly caused by staphylococci (45–55 %), particularly Staphylococcus aureus (33–43 %), and coagulase-negative staphylococci (17–21 %). However, other microorganisms can be involved such as streptococci (11–12 %) and more rarely Gram-negative bacteria (5–14 %), enterococci, and anaerobes. In 5–13 % of cases, mixed flora is found, while in 5 % of infections no microorganism is isolated (Giulieri et al. 2004; Laffer et al. 2006; Rao et al. 2008; Fulkerson et al. 2006).

Adhesion and fixation of bacteria onto biomaterial surfaces represent the first fundamental step in the development of PJI (Arciola et al. 2002).

Among various mechanisms involved in bacterial adhesion, the production of extracellular substance of polysaccharidic nature termed slime appears to play a relevant role; this phenomenon is now regularly referred to as biofilm formation (An and Friedmann 1998; Foster and McDevit 1994; Mack et al. 2000; Montanaro and Arciola 2000; Cristhensen et al. 1982).

It is well accepted that bacteria growing in a biofilm are more recalcitrant to the action of antibiotics than cells growing in a planktonic state and are associated with chronic inflammation and resistance to the innate immune system (Stewart and Costerton 2001).

More than 65 % and the majority of PJIs treated by clinicians in the developed world are now known to be caused by organisms growing in biofilm (Stoodley et al. 2011; Costerton et al. 1999).

The aim of this overview is to analyze the development of the biofilm and examine the most recent literature on this topic in particular about the efficiency of new and old treatments and possible perspectives for the future.



21.2 Bacterial Adhesion and Development of Biofilm


To understand the diagnostic principles and treatment models of PJI, it is imperative to understand the development and functions of biofilm. The transition from planktonic growth to biofilm occurs in response to environmental changes, such as the presence of a prosthetic device, and involves multiple regulatory networks. This communication termed “quorum sensing” (QS) is analogous to the paracrine signaling in multicellular organisms and enables the bacteria to regulate their gene synthesis (Gristina and Costerton 2009).

At the end, biofilm formation enables single-cell organisms to assume a temporary multicellular lifestyle, in which “group behavior” facilitates survival in adverse environments. What was once defined as the formation of a community of microorganisms attached to a surface has come to be recognized as a complex developmental process that is multifaceted and dynamic in nature (Kostakioti et al. 2013).

This cellular reprogramming alters the expression of surface molecules, nutrient utilization, and virulence factors and equips bacteria with an arsenal of properties that enable their survival in unfavorable conditions (Whiteley et al. 2001; Stanley et al. 2003; Vuong et al. 2004; Lenz et al. 2008).

As soon as a new device gets implanted in a surgical site, a process notoriously called “race for the surface” begins (Gristina et al. 1995).

According to this concept, there is a competition for colonizing the surface between extracellular matrix proteins (fibrinogen, fibronectin, vitronectin, thrombospondin, bone sialoprotein) and eukaryotic cells (fibroblasts, osteoblasts, endothelial cells) on one hand and prokaryotic bacterial cells on the other. Matrix proteins are known to cover foreign material as soon as it appears in the human body. In the next step, fibroblasts interact with a layer of matrix proteins using specific receptors called integrins. In such a way, the implant becomes covered by a viable barrier, capable of defense functions against bacteria. In case there are bacteria present at the time of implantation, they enter the competition for the surface, and the outcome largely depends on their number and features.

Bacterial adhesion to biomaterial surfaces and development of biofilm are thought to consist of four separate stages regulated through different mechanisms among which the best studied is QS (Lazar 2011; Costerton et al. 2007) (Fig. 21.2).

A318464_1_En_21_Fig2_HTML.jpg


Fig. 21.2
Four stages of biofilm formation. (Stage I) bacteria inoculated in planktonic form diffuse through fluids, initial adherence to the foreign body; (stage II) accumulation phase, irreversible binding to the surface the now sessile (or fixed) organisms begin to multiply and forming; (stage III) maturation, in this stage biofilms reach their ultimate thickness, generally greater than 100 μm with mushroom-shaped or tower-like microcolonies. At that stage the biofilm shows maximum resistance to antibiotics. (Stage IV) focal areas of the biofilm dissolve, so some of the bacteria develop the planktonic phenotype and leave the biofilm; such event may cause expansion of the infection and a reactivation of clinical manifestation

Stage I can be subdivided in to two phases. In the first, bacteria inoculated in planktonic form diffuse through fluids propelled by nonspecific physical factors like gravity, Brownian motion, surface tension, and van der Waals bonds. While this process for the majority of pathogen is at least in part stochastic, motile bacteria such as Pseudomonas aeruginosa have a competitive advantage. When bacteria come into proximity of an implant at distances smaller than 3 nm, they start interacting with biomaterial by means of hydrogen, ionic, and hydrophobic bonds. Energy needed for disruption of these bonds is small; therefore, initial attachment is dynamic and reversible (Donlan 2002; Krekeler et al. 1989; Kostakioti et al. 2013).

The second phase, mediated by multiple macromolecules able to bond with the implant surface and in general called adhesins, is less reversible. Microorganisms appear to have different adhesins for different surface materials (Hasty et al. 1992).

Pseudomonas aeruginosa, Escherichia coli, and others, mainly Gram-negative bacteria, connect to implant surface using flagella (Darouiche 2001). Flagella are protein hooks sized 20 nm used for grabbing the surroundings (An and Friedman 1998). Some bacterial species adhere to implant surface using specific means, e.g., Staphylococcus aureus uses MSCRAMM adhesive molecule (microbial surface components recognizing adhesive matrix molecules) to connect with extracellular matrix proteins covering the implant (Patti et al. 1994). Adhesion to a surface leads to important changes in many aspects of bacterial metabolism. Genes needed for biofilm development become activated. There are also other prerequisites for induction of this process like availability of nutrients, temperature, pH, osmolality, availability of iron, and presence of different signal molecules from other bacteria. During this stage, bacterial cells form a monolayer and exhibit a logarithmic grow rate.

Stage II, also called accumulation phase, is characterized by the irreversible binding to the surface and begins from minutes to hours after the first stage. Once adherence has taken place, the now sessile (or fixed) organisms begin to multiply and forming microcolonies while emitting chemical signals that “intercommunicate” between bacterial cells (Høiby et al. 2010a).

When the signal intensity exceeds a certain threshold level, the genetic mechanisms underlying extracellular polymeric substances (EPSs) production are activated. EPSs consist primarily of polysaccharides and contribute 50–90 % of the organic matter in biofilms. This matrix is highly hydrated (98 % water), and apart from water and microbial cells, it is a very complex material. Biofilm in fact is not only tenaciously bounded to the underlying surface but also has a propensity to act almost as filters to entrap particles of various kinds, including minerals and host components such as fibrin, RBCs, platelets, and planktonic bacteria (Costerton et al. 1999).

Therefore, all major classes of macromolecules (proteins, polysaccharides, and nucleic acids) are present in addition to peptidoglycan, lipids, phospholipids, and other cell components (Taraszkiewicz et al. 2013).

In case of Staphylococcal infection, this second stage is mediated by multiple molecules including polysaccharide intercellular adhesin (PIA)/poly-N-acetyl glucosamine (PNAG); proteins such as biofilm-associated protein (Bap), accumulation-associated protein (Aap), or fibronectin-binding protein (FnBp); and eDNA (Rohde et al. 2010).

Stage III is also known as maturation; it is characterized by the synthesis of tower-like structures containing, in part, eDNA from lysed bacteria and the generation of multiple metabolic niches that include bacteria growing under aerobic conditions, microaerobic-anaerobic conditions, dormant, and dead cells.

The production of QS signals bacterial surface components such as exopolysaccharides (EPSs) is required for the formation of a mature biofilm.

In this stage biofilms reach their ultimate thickness, generally greater than 100 μm with mushroom-shaped or tower-like microcolonies (Zoubos et al. 2012).

At this stage the biofilm shows maximum resistance to antibiotics (Høiby et al. 2010b).

Stage IV, during this stage, maybe due to bacteriophage activity within the biofilm, focal areas of the biofilm dissolve, so that some of the bacteria develop the planktonic phenotype and leave the biofilm, such event may cause metastatic expansion of the infection and a reactivation of clinical features (Webb et al. 2003; Gristina et al. 1987) (Figs. 21.3 and 21.4).

A318464_1_En_21_Fig3_HTML.jpg


Fig. 21.3
While bacteria in planktonic can be cleaned by host defense mechanisms and antibiotic, sessile forms are protected. Enzymes and other host defense mechanisms that enable to destroy biofilm and enzymes and other inflammatory molecules released may cause damage to the host cells. Such damage could be responsible of implant mobilization


A318464_1_En_21_Fig4_HTML.jpg


Fig. 21.4
Macroscopic aspect of a biofilm colony on a femoral knee prosthesis component explanted due to infection


21.3 Biofilm, a “Survival” or “Virulence” Mechanism for Bacteria


Using QS, biofilm bacteria behave very intelligently, adjusting the growth of colonies in response to various challenges; the complexity of biofilm structure and metabolism has led to the analogy of biofilms to tissues of more complex organisms (Costerton et al. 1995).

Living in biofilms, the bacteria are protected from deleterious conditions; this structure and its physiological attributes confer an inherent resistance to antimicrobial agents, whether these antimicrobial agents are antibiotics, disinfectants, or germicides. Cells in different regions of a biofilm exhibit different patterns of gene expression; likewise, growth, protein synthesis, and metabolic activity are stratified in biofilms (Davies et al. 1993).

Even if the structures that form biofilms contain channels in which nutrients can circulate (An YH and Friedmann RJ 1998), inspection of environmental as well as in vitro biofilms has revealed that the oxygen as well as nutrition concentration may be different in different areas of the matrix (Beer et al. 1994; Costerton et al. 1995).

Because of these nutritional and oxygen gradient, bacteria within a biofilm exist in different metabolic zones (Stewart and Franklin 2008). Nutrient-depleted zones can result in a stationary phase – like dormancy within the biofilm – which may be responsible for the general resistance of biofilms forming bacteria to antibiotics. Therefore, limited penetration of nutrients, rather than restricted antibiotic diffusion, may contribute to a generalized resistance or tolerance to antibiotics (Stoodley and Stoodley 2009).

Example of such metabolic heterogeneity is as described by Rani et al. (Rani et al. 2007) that S. epidermidis growing in a biofilm existed in four metabolic states: aerobic, fermentative growth, dead, and dormant.

Due to increased production of endogenous reactive oxygen species and a deficient antioxidant system, the mutation frequency of biofilm-growing bacteria is significantly increased compared with planktonically growing isogenic bacteria, and there is increased horizontal gene transmission in biofilms. Plasmid interchange is largely facilitated inside biofilm. The reason is the close proximity of bacteria; reduction of shear forces by the slime also eases conjugating process (Ehlers and Bouwer 1999).

These physiological conditions may explain why biofilm-growing bacteria easily become multidrug resistant by means of traditional resistance mechanisms against β-lactam antibiotics, aminoglycosides, and fluoroquinolones, which are detected by routine susceptibility testing in the clinical microbiology laboratory where planktonic bacterial growth is investigated. Thus, bacterial cells in biofilms may simultaneously produce enzymes that degrade antibiotics, have antibiotic targets of low affinity, and overexpress efflux pumps that have a broad range of substrates (Driffield et al. 2008; Molin and Tolker-Nielsen 2003).

The matrix can provide bacteria with protection also from host defense mechanisms. Bacterial cells inside the biofilm are well protected from complement system, neutrophilic granulocytes, killer cells, antibiotic peptides, antibodies, and phagocytosis. This impairment of host defense mechanisms has been demonstrated in a number of in vitro models.

Staphylococcus epidermidis is the paradigmatic example of virulence due to biofilm. Such a bacterium is generally not considered pathogenic, and its presence on normal skin and mucosal surface is not normally associated with any signs of inflammatory or immune reactions. However, the host-staphylococcal balance becomes disrupted if the bacterium gains entry into the tissues and especially if it reaches an orthopedic implant. After adhering to the implant surface, Staphylococcus epidermidis secretes a layer of slime that can inhibit the phagocytic activity of neutrophils (Shiau and Wu 1998) and decreases its antibiotic susceptibility significantly making this infection very hard to treat (Sousa 2011; Shiau and Wu 1998).


21.4 The Fight Against the Slime


As Roman’s said “divide et impera,” the better way to fight against biofilm forming bacteria is before the bacterial adherence to the foreign material has taken place, therefore before bacteria assume multicellular lifestyle. In such a “war,” the host, the wound, and all the environmental factors are involved. In the next pages, we will focus on antimicrobial prophylaxis, the role of the antimicrobial therapy in the treatment of PJI, and perspectives for the future possible new molecules and target.


21.4.1 Antimicrobial Prophylaxis


Perioperative antibiotic prophylaxis in orthopedic surgery is a broadly accepted practice, especially in prosthetic surgery (Borens et al. 2013).

It must be emphasized that perioperative antibiotic prophylaxis is not intended to sterilize tissues but to reduce the microbial burden of intraoperative contamination to a level that cannot overwhelm host defenses (Mangram et al. 1999). The goal is to achieve serum and tissue drug levels that exceed, for the duration of the operation, the minimum inhibitory concentration (MIC) for the organisms likely to be encountered during the operation (Bratzler and Houck 2004).

Important questions related to antibiotics before surgery are: which antibiotics to give, when to give, and for how long.


21.4.1.1 Which Antibiotics in Prophylaxis


In general, the selection of prophylactic antibiotic should be based on its spectrum of action, pharmacokinetics and safety profile, local hospital infections epidemiology and resistance patterns, antibiotics availability, and their relative cost. For practical reasons and due to better biodisponibility, prophylaxis is routinely given intravenously (i.v.).

In particular, in orthopedic prosthetic surgery, the agent must have a half-life that covers the decisive interval (the first 2 h after incision or contamination) with therapeutic tissue concentrations from the time of incision to wound closure and must be active against Staphylococcus aureus and Staphylococcus epidermidis which cause the majority of the implant-related infections (Rao 2008; Fulkerson 2006).

According to the present state of knowledge, cefazolin, the first-generation cephalosporin, is the most commonly studied and used for perioperative antibiotic prophylaxis in primary total joint replacement with a recommended dose of 1–2 g IV.

Cefazolin is preferred because of its activity against methicillin-sensitive Staphylococcus aureus (MSSA) and streptococci, for its safety profile, excellent distribution in the bone, muscle, and synovia, and low cost. Cefuroxime is a second-generation cephalosporin and has broader activity against Gram-negative bacteria than the first generation [61].

Recently cefuroxime at a dosage of 1.5 g i.v. has been recommended for total hip arthroplasty (Prokuski 2008; Bratzler and Hunt 2006; Kalman and Barriere 1990).

In case of a serious allergy or adverse reaction to β-lactams, although there are few data supporting its use for routine prophylaxis, clindamycin (600–900 mg) currently is the preferred alternative (Bratzler and Houck 2004; Gradl et al. 2011; Matar et al. 2010).

Patients with previous history of methicillin-resistant Staphylococcus aureus (MRSA) infection, institutions with high rate of MRSA (>10 %) and methicillin-resistant Staphylococcus epidermidis (MRSE) (>20 %) orthopedic surgical site infections (SSIs), and patients colonized with MRSA should undergo to perioperative prophylaxis with vancomycin (American Society of Health-System Pharmacists 2011).

Vancomycin has adequate activity against the most common high-resistant pathogens involved in orthopedic procedures, and it reaches high concentrations in the bone, synovia, and muscle within minutes after administration (Eshkenazi et al. 2001). It is important to keep in mind that the recommended dose should be adjusted to patient’s weight. A routine use of vancomycin should be discouraged since its routinely prophylactic use is associated with vancomycin-resistant Enterococcus colonization and infection (French 1998).


21.4.1.2 When to Give Antibiotics


The importance of antibiotic delivery timing is known since the 1970s when Miles and Burke established that the efficacy of antibiotics in reducing the dermal lesions after subcutaneous bacterial inoculation in a guinea pig model was associated with its administration during surgery or a few hours after wound closing. By delaying the administration of antibiotics by only 3 or 4 h, the resulting lesions were identical in size to those of animals not receiving antibiotic prophylaxis. This concept was confirmed in 1992 by Classen in a large study including surgical procedures performed in 2.847 patients in which 313 (11 %) were arthroplasty.

The authors found that the rate of infection was lower for patients who had received an antibiotic from zero to 2 h before the incision (Classen et al. 1992).

A study from Switzerland performed further investigations about the timing of prophylactic antibiotics. That study shows that administration of cefuroxime 59–30 min before incision is more effective than during the last half hour (Weber et al. 2008).

Hence, the American Academy of Orthopedic Surgeons (AAOS) recommends prophylactic antibiotics to be completely infused within 1 h before the surgical incision (American Academy of Orthopaedic Surgeons http://​www.​aaos.​org/​about/​papers/​ advistmt/​1027.​asp).

Other issues of antibiotic prophylaxis may be pointed out as follows:

1.

Dose amount should be proportional to patient weight; for patients >80 kg, the doses of cefazolin should be doubled.

 

2.

Vancomycin due to an extended infusion time, (10 mg/min or less to avoid infusion related events, i.e., “red man” syndrome) should be started within 2 h prior to incision. It is imperative to completely infuse antibiotic solution before surgical incision.

 

3.

Additional intraoperative doses of antibiotic are advised if:



  • The duration of the procedure exceeds one to two times the antibiotic’s half-life. As prophylaxis, cefazolin can be re-dosed every 2–5 h, cefuroxime every 3–4 h, clindamycin ever 3–6 h, and vancomycin every 6–12 h (American Society of Health-System Pharmacists 1999).


  • There is significant blood loss during the procedure (more than 1.5 l).

 


21.4.1.3 For How Long Antibiotics Must Be Administrated?


The duration of antibiotic prophylaxis in total joint arthroplasty is still controversial, and there is still insufficient evidence to support single-dose regimens. Mauerhan et al. compared the efficacy of a 1-day regimen of cefuroxime with a 3-day regimen in a prospective, double-blind, multicenter study of 1,354 patients treated with an arthroplasty and concluded that there was no significant difference in the prevalence of wound infections between the two groups (Mauerhan et al. 1994).

The current recommendation of the AAOS is that prophylactic antibiotics should be discontinued within 24 h of the end of surgery (Table 21.1) (American Academy of Orthopaedic Surgeons http://​www.​aaos.​org/​about/​papers/​ advistmt/​1027.​asp).


Table 21.1
Prophylaxis recommendations during prosthetic surgery























 
Institution with

<10 % SSIs MRSA

<20 % SSIs MRSE

Institution with

>10 % SSIs MRSA

>20 % SSIs MRSE

Cefazolin 1–2 g IV

or

Cefuroxime 1.5 g IV

X

X

Vancomycin 1 g IV

_

X

Patients with adverse reaction to β-lactams clindamycin 600–900 mg iv

X

X


21.4.2 The Role of Antibiotic Therapy After PJI


The management of PJI generally relies on a combination of antimicrobial therapy and surgery. Two-stage reimplantation is considered the standard surgical procedure (Fig. 21.5) while other surgical strategies include: one-stage exchange procedures, resection arthroplasty, amputation, and debridement and retention. The latter can be considered in patients with a short duration of symptoms (patients diagnosed with a PJI within approximately 30 days from prosthesis implantation or <3 weeks of onset of infectious) in the absence of implant loosening and soft tissue damage. Finally, whenever surgical procedures cannot be performed and infected prosthesis is retained, a chronic suppressive antibiotic treatment is advisable (Laffer, et al. 2006; Matthews et al. 2009; Trampuz and Zimmerli 2008; Zimmerli, et al. 2004, 1998; Stewart and Costerton 2001).

A318464_1_En_21_Fig5_HTML.jpg


Fig. 21.5
(a) X-ray showing a mobilization of a revision knee prosthesis due to infection, (b) intraoperative picture of the cement spacer used during two-stage exchange, (c) X-ray of the cement spacer, (d) X-ray 1 year after the spacer removal

In any case, it is of paramount importance the use of pathogen-targeted and biofilm-active antibiotics, particularly in case of retention of the prosthesis.

Guidelines on the management of prosthetic joint infections have been issued in 2013 by the Infectious Diseases Society of America (IDSA), and pathogen-targeted options are reported in Table 21.2 (Osmon et al. 2013).


Table 21.2
Adapted and simplified IDSA guidelines on the management of prosthetic joint infections









Microorganism

Only gold members can continue reading. Log In or Register to continue

Sep 22, 2016 | Posted by in ANESTHESIA | Comments Off on The Fight Against the Slime: Can We Ever Win?

Full access? Get Clinical Tree

Get Clinical Tree app for offline access